|
Post by scottmnkd on May 1, 2019 18:03:54 GMT -5
Young, energetic, hard-working, smart, connected, experienced but not so much that he is inflexible. If I was a short, I would be attacking the best thing Mannkind has going for it, Mike C. Just relate it to turning around a cruise ship rather than a speed boat. What is the experience you claim he has. This is his first CEO position. I suggest you check his resume. My thought exactly. Mike C is a pharmacist with a PHD. He was not trained to be a CEO with an MBA. He was brought into the company to head-up marketing. Sorry, folks, I know it has been a struggle, but I haven't seen any stellar results, and we need stellar results. I think the only way we can get there is to bring on someone who has a track record of leading sales teams, brokering international deals, and getting the insurance companies to pay. Nothing against Mike personally, but broken promises and our Christmas surprise haven't gotten us very far yet. In fact, most of us are in the red (if you're long). Leadership matters - a lot!
|
|
|
Post by longliner on May 1, 2019 18:25:39 GMT -5
Young, energetic, hard-working, smart, connected, experienced but not so much that he is inflexible. If I was a short, I would be attacking the best thing Mannkind has going for it, Mike C. Just relate it to turning around a cruise ship rather than a speed boat. It looks like you hit a nerve.😉
|
|
|
Post by olebob1 on May 1, 2019 18:53:10 GMT -5
What is the experience you claim he has. This is his first CEO position. I suggest you check his resume. "Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs and Vice President, Global Lifecycle Management. Prior to Amgen, Dr. Castagna, was Executive Director of Bristol-Myers Squibb’s Immunology franchise, where he served as co-lead to relaunch Orencia IV and launch Orencia SC, both rheumatoid arthritis drugs. Before BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and Division Head for Biopharmaceuticals, North America, where he established the US Biologics Business Unit and relaunched its lead product, Omnitrope, a human growth hormone. Prior to Sandoz, Dr. Castagna held a variety of positions with EMD (Merck), Serono, Pharmasset and DuPont Pharmaceuticals. Dr. Castagna has been Director of MannKind Corporation since May 25, 2017. Dr. Castagna serves on the board of directors of Pet Partners headquartered in Bellevue, Washington. Dr. Castagna received his Bachelors of Science – Pharmacy degree from Philadelphia College of Pharmacy, his Doctor of Pharmacy from Massachusetts College of Pharmacy and his MBA from the Wharton School of Business at the University of Pennsylvania." Every CEO was a first time CEO. Maybe the choice off words are being parsed here and that may be intentional on your part, but he does have experience in the healthcare industry. Honestly, name a POTUS that has had experience as being POTUS before the first time? Give it a break man. Hello Dolly, Thanks for posting Dr. Castagna's resume for those in doubt. Looks pretty strong to me. Thanks!
|
|
|
Post by radgray68 on May 1, 2019 18:56:54 GMT -5
Well then......I don't know what to tell you. You just aren't looking hard enough. Remove the stock price, the pain, the time, the worry. Now, is the business heading in the right direction? Yes.
To back it up, I'm buying hand over fist as much as I can. But,(and it's a big but) I have a 5-7 year horizon. That makes a huge difference in how you and I would view the company. Good luck to you.
|
|
|
Post by nylefty on May 1, 2019 19:07:34 GMT -5
What is the experience you claim he has. This is his first CEO position. I suggest you check his resume. My thought exactly. Mike C is a pharmacist with a PHD. He was not trained to be a CEO with an MBA. Huh? He has a MBA from Wharton. Does his PHD in Pharmacy somehow negate that?
|
|
|
Post by lifebreath on May 1, 2019 19:16:08 GMT -5
What is the experience you claim he has. This is his first CEO position. I suggest you check his resume. "Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs and Vice President, Global Lifecycle Management. Prior to Amgen, Dr. Castagna, was Executive Director of Bristol-Myers Squibb’s Immunology franchise, where he served as co-lead to relaunch Orencia IV and launch Orencia SC, both rheumatoid arthritis drugs. Before BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and Division Head for Biopharmaceuticals, North America, where he established the US Biologics Business Unit and relaunched its lead product, Omnitrope, a human growth hormone. Prior to Sandoz, Dr. Castagna held a variety of positions with EMD (Merck), Serono, Pharmasset and DuPont Pharmaceuticals. Dr. Castagna has been Director of MannKind Corporation since May 25, 2017. Dr. Castagna serves on the board of directors of Pet Partners headquartered in Bellevue, Washington. Dr. Castagna received his Bachelors of Science – Pharmacy degree from Philadelphia College of Pharmacy, his Doctor of Pharmacy from Massachusetts College of Pharmacy and his MBA from the Wharton School of Business at the University of Pennsylvania." Every CEO was a first time CEO.  Maybe the choice off words are being parsed here and that may be intentional on your part, but he does have experience in the healthcare industry.  Honestly, name a POTUS that has had experience as being POTUS before the first time?  Give it a break man. Absolutely not true!! Castagna is 41 years old graduates from college age 22 maybe 21, pharmaceutical college to achieve pharma D is four years. Makes him 25, Wharton mba is a three year program 28 Years old 3 years at Mannkind. Leaves a possibility of 10 years work experience. Can you preform simple Arithmetic ? Having years of CEO experience for this position is crucial. He is being compensated $1 million per year to try and learn on the job
|
|
|
Post by longliner on May 1, 2019 19:19:33 GMT -5
"Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs and Vice President, Global Lifecycle Management. Prior to Amgen, Dr. Castagna, was Executive Director of Bristol-Myers Squibb’s Immunology franchise, where he served as co-lead to relaunch Orencia IV and launch Orencia SC, both rheumatoid arthritis drugs. Before BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and Division Head for Biopharmaceuticals, North America, where he established the US Biologics Business Unit and relaunched its lead product, Omnitrope, a human growth hormone. Prior to Sandoz, Dr. Castagna held a variety of positions with EMD (Merck), Serono, Pharmasset and DuPont Pharmaceuticals. Dr. Castagna has been Director of MannKind Corporation since May 25, 2017. Dr. Castagna serves on the board of directors of Pet Partners headquartered in Bellevue, Washington. Dr. Castagna received his Bachelors of Science – Pharmacy degree from Philadelphia College of Pharmacy, his Doctor of Pharmacy from Massachusetts College of Pharmacy and his MBA from the Wharton School of Business at the University of Pennsylvania." Every CEO was a first time CEO.  Maybe the choice off words are being parsed here and that may be intentional on your part, but he does have experience in the healthcare industry.  Honestly, name a POTUS that has had experience as being POTUS before the first time?  Give it a break man. Absolutely not true!! Castagna is 41 years old graduates from college age 22 maybe 21, pharmaceutical college to achieve pharma D is four years. Makes him 25, Wharton mba is a three year program 28 Years old 3 years at Mannkind. Leaves a possibility of 10 years work experience. Can you preform simple Arithmetic ? It would seem you are to short to see over the table.🤣
|
|
|
Post by nylefty on May 1, 2019 19:29:04 GMT -5
"Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs and Vice President, Global Lifecycle Management. Prior to Amgen, Dr. Castagna, was Executive Director of Bristol-Myers Squibb’s Immunology franchise, where he served as co-lead to relaunch Orencia IV and launch Orencia SC, both rheumatoid arthritis drugs. Before BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and Division Head for Biopharmaceuticals, North America, where he established the US Biologics Business Unit and relaunched its lead product, Omnitrope, a human growth hormone. Prior to Sandoz, Dr. Castagna held a variety of positions with EMD (Merck), Serono, Pharmasset and DuPont Pharmaceuticals. Dr. Castagna has been Director of MannKind Corporation since May 25, 2017. Dr. Castagna serves on the board of directors of Pet Partners headquartered in Bellevue, Washington. Dr. Castagna received his Bachelors of Science – Pharmacy degree from Philadelphia College of Pharmacy, his Doctor of Pharmacy from Massachusetts College of Pharmacy and his MBA from the Wharton School of Business at the University of Pennsylvania." Every CEO was a first time CEO. Maybe the choice off words are being parsed here and that may be intentional on your part, but he does have experience in the healthcare industry. Honestly, name a POTUS that has had experience as being POTUS before the first time? Give it a break man. Absolutely not true!! Castagna is 41 years old graduates from college age 22 maybe 21, pharmaceutical college to achieve pharma D is four years. Makes him 25, Wharton mba is a three year program 28 Years old 3 years at Mannkind. Leaves a possibility of 10 years work experience. Can you preform simple Arithmetic ? So you never worked while also going to school? Lots of people do (and that's what MC did). /
|
|
|
Post by mytakeonit on May 1, 2019 19:37:39 GMT -5
Hey! I resemble that remark !!!
But, that's mytakeonit
|
|
|
Post by pat on May 1, 2019 19:57:25 GMT -5
DTC sales.
That’s what I’m waiting on.
Everything else is white noise.
|
|
|
Post by morfu on May 1, 2019 20:19:55 GMT -5
Mike C. seems to be getting a ton of criticism on the Message Boards lately, but is the criticism fair? To answer that question, you would have to know where the criticism is coming from and why some may be criticizing. For the most part; the crux of the criticism seems to be coming from Shorts and individuals who would gain from MNKD's failure. They criticize Mike perhaps because they are afraid, maybe even frightened that he will soon right the ship and put them out of commission for good. This may be somewhat more imminent in nature than many may think. The more they bash Mike and MNKD management, the more they stand to gain. It's the best card that they have to play right now, and they are playing it to death. One rhetorical question may be this, 'If Mike is doing such a bad job, and if things are going the way that your bosses want them to go, why shed light on it?' Why not be quiet and let Mike steer the ship into the bottom of the ocean?
On the other hand, there are some long-term holders that may be criticizing Mike out of frustration. Perhaps one of the most difficult tasks is to get on a ship and have no idea where it's heading. One can guess, while others may cling to every nuance of the Captain, but at the end of the day frustration sets in when no one has a clue where the ship will dock. Will it dock on a paradise like Island? On a deserted terrain? Or will it find itself at the bottom of the ocean? This will cause some to jump overboard in fear and frustration only to drown or turn around and lose mostly everything that they've boarded this ship with. While others on board may sit back and listen to a quartet play a string of tunes while downing their favorite bourbon, wondering in the back of their minds if they should feel so relaxed.
Wherever the criticism may come from, we have to admit that it exists. Is it fair? For some YES, while for others, NO. I continue to say that Mike should be more vocal in regards to MNKD making noise about Al Mann's amazing product! We cannot win a traditional battle because these Corporations and Big Pharmas are too experienced in fighting those types of battles. Fight 'em through unique advertising; Lower A1C's with no needles. Fight 'em with testimonials on Websites. Fight 'em on Twitter; letting everyone know where we are heading and how we plan to get there. Fight 'em with uniqueness; cool color dreamboats and novelty.
At the end of the day, wherever we dock; we can all say that we put up the fine fight and the Captain stayed in control and then I will take a sip of bourbon and admire the beauty of a paradise Island.
That's My Take On it, no pun intended. What's yours - Is the Criticism Fair? Well, I am not short and not frustrated, yet I criticized and criticize his decision in December to giveaway 20% of my/our property without any benefit! The 40mil$ he got for that are not needed and a joke compared to the potential value of 20% of this company. Since he had plenty opportunity to explain this decision and didn`t, I can point out at best it was a mistake or we can dive into conspiracy.. Dont tell me that this company at the current state cannot borrow 40mil$ easily.
|
|
|
Post by uvula on May 1, 2019 20:32:26 GMT -5
The current state is the company is not profitable. Makes raising any money difficult.
|
|
|
Post by nylefty on May 1, 2019 21:11:53 GMT -5
"Dont tell me that this company at the current state cannot borrow 40mil$ easily."
Easily? Talk about being delusional!
|
|
|
Post by letitride on May 1, 2019 21:19:26 GMT -5
Ever since I learned how to use the ignore feature criticism has become very illusive.
|
|
|
Post by morfu on May 1, 2019 21:22:53 GMT -5
The current state is the company is not profitable. Makes raising any money difficult. Closer to profitable and less in debt than last time he raised money. In fact I think this quarter willbe profitable and so was the last one even without the 40mil$
(one of the reasons I claim this dilution was not needed)
|
|